What is Sinphar Pharmaceutical Co Cash Flow from Financing?
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Dec. 2024,
Sinphar Pharmaceutical Co paidNT$0 Mil more to buy back shares than it received from issuing new shares.
It receivedNT$87 Mil from issuing more debt.
It paidNT$0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It receivedNT$0 Mil from paying cash dividends to shareholders.
It spentNT$168 Mil on other financial activities.
In all, Sinphar Pharmaceutical CospentNT$81 Mil on financial activities for the
three
months ended in Dec. 2024.
Sinphar Pharmaceutical Co Cash Flow from Financing Historical Data
The historical data trend for Sinphar Pharmaceutical Co's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Sinphar Pharmaceutical Co Cash Flow from Financing Chart
Sinphar Pharmaceutical Co Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Sinphar Pharmaceutical Co's Cash from Financing for the fiscal year that ended in Dec. 2024 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-209 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinphar Pharmaceutical Co (TPE:1734) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Sinphar Pharmaceutical Co's issuance of stock for the
three
months ended in Dec. 2024 was NT$0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Sinphar Pharmaceutical Co's repurchase of stock for the
three
months ended in Dec. 2024 was NT$0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Sinphar Pharmaceutical Co's net issuance of debt for the
three
months ended in Dec. 2024 was NT$87 Mil.
Sinphar Pharmaceutical Co receivedNT$87 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Sinphar Pharmaceutical Co's net issuance of preferred for the
three
months ended in Dec. 2024 was NT$0 Mil.
Sinphar Pharmaceutical Co paidNT$0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Sinphar Pharmaceutical Co's cash flow for dividends for the
three
months ended in Dec. 2024 was NT$0 Mil.
Sinphar Pharmaceutical Co receivedNT$0 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Sinphar Pharmaceutical Co's other financing for the
three
months ended in Dec. 2024 was NT$-168 Mil.
Sinphar Pharmaceutical Co spentNT$168 Mil on other financial activities.
Sinphar Pharmaceutical Co Cash Flow from Financing Related Terms
Thank you for viewing the detailed overview of Sinphar Pharmaceutical Co's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.
Sinphar Pharmaceutical Co Ltd operates in the pharmaceutical segment. The company mainly engages in the production, processing, and trading of various Chinese medicines, medicinal cosmetics, and nutrients. The company's reportable segments are; Pharmaceuticals which derives key revenue, Healthy food, and others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from China, Vietnam, Indonesia, America, and other regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TPE:1734 has been successfully added to your 